fluoxetine + imipramine

Fluoxetine + imipramine is a combination of two antidepressant drugs, each with distinct mechanisms of action. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin levels by inhibiting its reuptake in the central nervous system. Imipramine is a tricyclic antidepressant (TCA) that inhibits the reuptake of both serotonin and norepinephrine, while also blocking histamine H1, α1-adrenergic, and muscarinic receptors. This combination may be considered in treatment-resistant depression but carries significant risk for adverse effects such as sedation, anticholinergic symptoms (dry mouth, blurred vision, constipation), and potentially life-threatening interactions like serotonin syndrome due to additive serotonergic activity[1][6][8]. The use of this combination should be closely monitored by healthcare professionals.